Scientists
  • ● Faculty and Staff
Name:
Xing-Jie Liang
Education:
Ph.D
Positions:
Deputy Director of the Laboratory of Biological Effects of Nanomaterials and Nanosafety
Academic title:
Professor
Postal Code:
100190
Subject categories:
Nanomedicine
Mailing Address:
No.11,Beiyitiao Zhongguancun Beijing,china
E-mail:
liangxj(AT)nanoctr.cn

Resume:

  Dr. Xing-Jie Liang got his Ph.D at National Key Laboratory of Biomacromolecules, Institute of Biophysics, Chinese Academy of Sciences. He finished his postdoc with Dr. Michael M. Gottesman (Deputy Director of NIH, USA) for 5 years at Laboratory of Cell Biology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, Maryland. Then, he worked as a Research Fellow at Surgical Neurology Branch, NINDS (National Institute of Neurological Diseases and Strokes, NIH) for 2 years. In 2007, he was an Assistant professor at Department of Radiology, School of Medicine, Howard University. Dr. Liang currently is deputy director of Key Laboratory for Biomedical Effects of Nanomaterials and Nanosafety, Chinese Academy of Sciences and Lab Chief of Laboratory of Controllable Nanopharmaceuticals, National Center for Nanoscience and Technology of China. Dr. XingJie Liang is a founder member of International Society of Nanomedicine, member of American Association for Cancer Research, and member of American Society of Cell Biology. Dr. Xing Jie Liang is also deputy director of Nanomedicine and Nanopharmaceuticals Committee at Society of Nanobiology and Nanomedicine and Deputy Director of Nanomedicinal Materials committee of Chinese Society of Biomaterials.     

  Dr. Xing-Jie Liang is current deputy Editor-in-Chief of Biophysics Reports and Associate Editor of Biomaterials, Advisary Board Member of ACS Nano. He is also current editorial board member of current nanoscience, Biomaterials Research,Theranosticsand guest editor of Biotechnology Advances.     

  The current researches include three topics ongoing in the laboratory.  

  1. Nanotherapy: FDA approved materials developed with nanotechnologies to improve the bioavailability and therapeutic efficancy as well as to decrease toxicity of chemocompounds or bio-drugs (genes or proteins) by targeted delivery and controllable release;  

  2. Nanoimmunology: Unique immunological responses of nanomaterials and nanoadjuvants by different administration in vivo:  

  3. Nanobiotechnology: Nanostructures to solve the medicinal or pharmaceutical toughest problems (MDR, stem cells development etc): 

  4. Nanoplatform: Nanoscale DDS for Chemo-/Gene-Therapy; Nano-AIE for Pharmadynamic/Kinetic evaluation. 

  In addition, another topic on nanoimaging is another interested field in his group.  

  5. Nanoimaging and Nanodiagnosis:  Nanopharmaceuticals ADMET in vivo by various techniques (Nano SPECT/CT, Acoustic ultrasound, In vivo Imaging, MRI, Bio-TEM etc) 

  His researchs are to develop nanopharmaceuticals for clinical trials and transfer FDA-certified licensess to pharmaceutical companies for production. This mission is from his interests in elucidating mechanisms to improve nanomedicinal bioavailability by nanotechnology in vivo, and developing novel strategies to increase therapeutic effect on cancers and infectious diseases. Improved drug delivery efficiency for prevention/treatment of AIDS and cancers are under investigation in Dr. Liang's lab based on understanding of basic physio-chemical and biological processes of nanodrugs. Most protocols are employed for delivering therapeutic molecules to actively target cells or tissues in vivo to enhance drug safety and efficacy. Dr. Liang’s current research activities include: Nanotherapeutics for diseases treatment; Nanoparticle interactions with biological membranes; Nanotechnology to circumvent multidrug resistance of cancer; Nanobiomedicine and nanosafety; Nanotechnology to improve the vaccine immunogenicity; Nanomaterials imaging in vitro and in vivo.    

    

Direction:

nanomedicine and nanopharmaceuticals 

Achievements:

 2004 2005 and 2006 "Fellows Award for Research Excellence" National Institute of Health, USA. “Special Government Allowances” by Department of State, 2011; “National Distinguished Young Scholars” by NSFC; “Young Pharmaceutics Scholar” by CPA, 2012; “Outstanding Research Award” to hundred elite researcher of CAS, 2013; “Natural Science Research Award” by HeBei Province Bureau of Science and Technology, 2014; and “Inspection Improve Award” by General Administration of Quality Supervision, Inspection and Quarantine of the People’s Republic of China, 2014.Adjuvant Professor of Chinese Academy of Medical Sciences and Peking Union Medical College, Institute of Biomedical Engineering. 

Article:

Representive publications*


  1. Wei T, Chen C, Liu J, Liu C, Posocco P, Liu X, Cheng Q, Huo S, Liang Z, Fermeglia M, Pricl S, Liang XJ*, Rocchi P, Peng L*. Anticancer drug nanomicells formed by self-assembling amphiphilic dendrimers to combat cancer drug resistence. PNAS. 2015. DOI: 10.1073/pnas.1418494112

  2. Song Y, Zhang T, Song X, Zhang L, Zhang C, Xing J and Liang XJ*. Polycations with excellent gene transfection ability based on PVP-g-PDMAEMA with random coil and micelle structures as non-viral gene vectors. Journal of Materials Chemistry B. 2014. DOI: 10.1039/C4TB01754D.

  3. Zhang C, Li Y, Xue X, Chu P, Liu C, Yang K, Jiang Y, Chen W, Zou G, Liang XJ*. A smart pH-switchable luminescent hydrogel. Chem Commun. 2015 DOI: 10.1039/C4CC09861G.(cover figure)

  4. Xiangdong Xue,Yuanyuan Zhao, Xu Zhang, Chunqiu Zhang, Anil Kumar, Xiaoning Zhang, Guozhang Zou, Paul C. Wang, Jinchao Zhang, Xing-Jie Liang*. Phenylboronic Acid Functionalized Magnetic Nanoparticles for One-step Saccharides Enrichment and Mass Spectrometry Analysis. Biophysics Report. 2015. DOI:

  5. Jimei Zhang, Chan Li, Xu Zhang, Shuaidong Huo, Shubin Jin, Fei-Fei An, Xiaodan Wang, Xiangdong Xue, Okeke C. I , Guiyun Duan, Fengguang Guo, Xiaohong Zhang, Jifu Hao, Paul C. Wang, Jinchao Zhang, Xing-Jie Liang*. In vivo tumor-targeted dual-modal fluorescence/CT imaging using a nanoprobe co-loaded with an aggregation-induced emission dye and gold nanoparticles. Biomaterials. 2015.(4) 103-111.

  6. Chunqiu Zhang, Xiangdong Xue, Quan Luo, Yiwei Li Keni Yang, Xiaoxi Zhuang, Yonggang Jiang, Jinchao Zhang, Junqiu Liu, Guozhang Zou and Xing-Jie Liang*. Self-Assembled Peptide Nanofibers Designed as Biological Enzymes for Catalyzing Ester Hydrolysis. ACS Nano. 2014. 25;8(11):11715-23

  7. Yuran Huang, Tuo Wei, Jing Yu, Yanglong Hou, Kaiyong Cai*, Xing-Jie Liang*. Multifunctional Metal Rattle-Type Nanocarriers for MRI-Guided Photothermal Cancer Therapy. Molecular Pharmaceutics 2014. 11(10):3386-3394.

  8. Xue X, Wang L, Sato Y, Jiang Y, Berg M, Yang DS, Nixon R, Liang XJ*. Single-walled carbon nanotubes alleviate autophagic/lysosomal defects in primary glia from a mouse model of Alzheimer's disease. Nano Lett. 2014 14(9):5110-5117.

  9. Shuaidong Huo, Shubin Jin, Xiaowei Ma, Xiangdong Xue, Keni Yang, Paul C. Wang, Jinchao Zhang, Zhongbo Hu, and Xing-Jie Liang. Ultra-small Gold Nanoparticles as Carriers for Nucleus-based Gene Therapy Due to Size-dependent Nuclear Entry. ACS nano. 2014. 24;8(6):5852-5862.

  10. Xing-Jie Liang. Nanotechnology and Cancer Nanomedicine. Biotechnology Advances 2014.32(4): 665. (editorial comments)

  11. Liu J, Huang Y, Kumar A, Tan A, Jin J, Mozhi A, Liang XJ*. pH-Sensitive nano-systems for drug delivery in cancer therapy. Biotechnology Advances 2014.32(4): 693-710.

  12. Xue X, Hall M, Zhang Q, Wang P, Gotteman MM, Liang XJ *. Nanoscale Drug Delivery Platforms Overcome Platinum-Based Resistance in Cancer Cells Due to Abnormal Membrane Protein. ACS Nano. 2013. 23;7(12):10452-10464.

  13. Xue X, Zhao Y, Dai L, Zhang X, Hao X, Huo S, Liu J, Liu C, Kumar A, Zou,G* Liang XJ*. Spatiotemporal Drug Release Visualized Through a Drug Delivery System with Tunable Aggregation-Induced Emission. Advanced Materials. 2014. 26(5):712-717

  14. Han L.; Zhao J.; Liu J.; Duan X.; Wei Y.; Liang XJ*. A universal gene carrier platform for treatment of human prostatic carcinoma by p53 transfection. Biomaterials. 2014 35(9):3110-3120.

  15. Yan Li, Qiang Cheng, Qian Jiang, Yuanyu Huang, Hongmei Liu, Yuliang Zhao, Weipeng Cao, Guanghui Ma, Fengying Dai, Xing-Jie Liang*, Zicai Liang, Xin Zhang*. Enhanced endosomal/lysosomal escape by distearoyl phosphoethanolamine - polycarboxybetaine lipid for systemic delivery of siRNA. Journal of Controlled Release. 2014,176: 28:104–114.

  16. Sun Y, Cao W, Li S, Jin S, Hu K, Hu L, HuangY, GaoX, Wu Y*, Liang XJ*. Ultrabright and multicolorful fluorescence of Amphiphilic Polyethyleneimine polymerdots for efficiently combined imaging and therapy. Scientific Reports 2013. 3:3036.

  17. Kumar A, Chen F, Mozhi A, Zhang X, Zhao Y, Xue X, Hao Y, Zhang X, Wang PC, Liang XJ*. Innovative pharmaceutical development based on unique properties of nanoscale delivery formulation. Nanoscale. 2013, 5 (18), 8307 – 8325.

  18. Wei T, Liu J, Ma H, ChengQ, Huang Y, Zhao J, Huo S, Xue X, Liang Z, Liang XJ *. Functionalized nanoscale micelles improve the drug delivery for cancer in vitro and in vivo. Nano Letter. 2013. 13(6):2528-2534.

  19. Kumar A, Zhang X, Liang, X.J*. Gold Nanoparticles: Emerging Paradigm for Targeted Drug Delivery System. Biotechnology Advances. 2013 (31):593-606.

  20. Gil P, Aberasturi D, Wulf V, Pelaz B, Pino P, Zhao Y, Fuente J, Larramendi, Teófilo Rojo I, Liang, X.J, Parak W. The challenge to relate physico-chemical properties of colloidal nanoparticles to their cytotoxicity. Accounts of Chemical Research. 2013.46(3):743-749.

  21. Jia L, Lu Y, Shao J, Liang XJ, Xu Y. Nanoproteomics: a new spout from emerging links between nanotechnology and proteomics. Trends in Biotechnology, 2013. Feb 31(2): 99-107.

  22. Huo S, Ma H, Huang K, Liu J, Wei T, Jin S, Zhang J, He S and Liang, X.J*. Superior penetration and retention behavior of 50nm gold nanoparticles in tumor. Cancer Research, 2013 73:319-330.

  23. Hua D, Zhang X, Zou G, Kumar A, Zhang X and Liang, X.J*. Long genomic DNA amplicons adsorption onto unmodified gold nanoparticles for colorimetric detection of Bacillus anthracis. Chemical Communication. 2013, 49(1): 51-53.

  24. Ma X, Zhang L, Wang L, Xue X, Sun J, Wu Y, Zou G, Wu X, Wang P, Wamer W, Yin J, Zheng K, Liang, X.J*. Single-walled Carbon Nanotubes Alter Cytochrome C Electron Transfer and Modulate Mitochondrial Function. ACS Nano, 2012. 21;6(12):10486-96

  25. Han L, Zhao J, Zhang X, Cao W, Hua X, Zou G, Duan X, Liang, X.J*. Simple charge-reversal polymer assembly nanosystem with good biocompatibility for enhanced siRNA delivery and silencing. ACS Nano, 2012. 28; 6(8):7340-51.

  26. Huang Y, He S, Cao W, Cai K and Liang, X.J*. Biomedical nanomaterials for imaging-guided cancer therapy. Nanoscale. 2012, 4 (20), 6135 – 6149.

  27. Jiang Q, Song C, Nangreave J, Liu X, Lin L, Qiu D, Wang Z, Zou G, Liang, X.J, Yan H, Ding B. DNA Origami as a Carrier for Circumvention of Drug Resistance. JACS. 2012. 134 (32), pp 13396–13403.

  28. Huang K, Ma H, Liu J, Huo S, Kumar A, Wei T, Zhang X, Jin S, Gan Y, Wang P, He S, Zhang Xand Liang, X.J*. Size-Dependent Localization and Penetration of Ultrasmall Gold Nanoparticles in Cancer Cells, Multicellular Spheroids, and Tumors in vivo. ACS Nano. 2012. 6 (5), 4483–4493. Commented on News and Views. Nanomedicine (2012) 7(7), 945–948.

  29. Zhang X, Wu D, Shen X, Chen J, Sun Y, Liu P, Liang, X.J*. Size-dependent radiosensitization of PEG-coated gold nanoparticles for cancer radiation therapy. Biomaterials. 2012. 33(27):6408-19.

  30. Liu, J, Ma, H., Wei, T. and Liang, X.J*.. CO2 gas induced drug release from pH-sensitive liposome to circumvent doxorubicin resistant cells. Chemical Communication. 2012. 48, 4869–4871

  31. Ma, H, Jiang, Q., Han, S.Y., Wu, Y., Li T., Wang D., Gan, Y.L., Zou, G.Y.*, and Liang, X.J.*. Multicellular Tumor spheroids (MCTSs) as an in vivo-like model for 3D Imaging of Chemotherapeutics and Nano Materials Penetration. Molecular Imaging, 2012. 11(6): 487-98.

  32. Liu Z and Liang, X.J*. Nano-Carbons as Theronostics.. Theranostic. 2012, 2(3): 235-237. (Editorial comment)

  33. Kumar, A., Ma, H., Zhang, X., Huang, K., Jin, S.B., Liu, J., Wei, T., Cao, W.P., Liang, X.J*. Ultra Small Gold Nanoparticles Fabricated with Therapeutic and Targeted Peptides for Cancer Treatment. Biomaterials 2012. 33(4): 1180-1189.

  34. Xue, X., You, S., Zhang, Q., Wu, Y., Zou, G.Z., Wang, P.C., Zhao, Y., Xu, Y., Jia, L., Zhang, X., Liang, X.J*. Mitaplatin increases sensitivity of tumor cells to cisplatin by inducing mitochondrial dysfunction. Molecular Pharmaceutics, 2012, 9 (3): 634−644.

  35. Deng, H., Xu, Y., Liu, Y.H., Che, Z.J., Guo, H.L., Shan, S., Sun, Y., Liu, X., Huang, K., Ma, X.W., Wu, Y. and Liang, X.J*. Gold nanoparticles with asymmetric polymerase chain reaction for rapid colorimetric detection of DNA sequence. 2011. Analytical Chemistry, 2012, 2012, 84 (3): 1253–1258.

  36. Ma, X.W., Wu, Y., Jin, S.B., Tian.Y., Zhang, X.N., Zhao.Y., Yu, L. and Liang, X.J*. Gold Nanoparticles Induce Autophagosome Accumulation through Size-Dependent Nanoparticle Uptake and Lysosome Impairment. ACS Nano. 2011. 5 (11): 8629–8639.

  37. Ma, X.W., Zhao, Y., Liang, X.J*. Theranostic Nanoparticles engineered for Clinic and Pharmaceutics. Accounts of Chemical Research. 2011. 44(10): 1114–1122.

  38. Guo, S.T., Huang, Y., Wei, T., Wang, W.D., Wang, W.W., Lin, D., Zhang, X., Kumar, A., Du, Q., Xing, J., Deng, L., Liang, Z., Wang, P., Dong A., and Liang, X.J.* Amphiphilic and Biodegradable Methoxy Polyethylene glycol-block-(polycaprolactone-graft-poly (2-(dimethylamino)ethyl methacrylate)) as an Effective Gene Carrier. Biomaterials, 2011, 32: 879-889.

  39. Guo, S.T., Huang, Y., Jiang, Q., Sun, Y., Deng, L., Liang, Z., Du, Q., Xing, J., Zhao, Y., Wang, P., Dong A., and Liang, X.J.*. Enhanced Gene Delivery and siRNA Silencing by Gold Nanoparticles Coated with Charge-reversal Polyelectrolyte. ACS Nano. 2010. 4(9): 5505-5511.

  40. Liang, X.J. *, Meng, H., Wang, Y., He, H., Meng, J., Lu, J., Wang, P. C., Zhao, Y., Gao, X., Sun, B., Chen, C., Xing, G., Shen, D., Gottesman, M. M., Wu, Y., Yin, J.J., Jia, L. Metallofullerene Nanoparticles Circumvent Tumor Resistance to Cisplatin by Reactivating Endocytosis. Proc Natl Acad Sci U S A. 2010. 107(16):7449-7454.

  41. Ma, X.W., Wang, D., Wu, Y., Ho, RJY, Jia, L., Guo, P., Hu, L., Xing, G., Zeng, Y., Liang, X.J*. AIDS Treatment with Novel Anti-HIV Compounds Improved by Nanotechnology. AAPS J. 2010, 12(3):272-278.

  42. Xing, J, Deng, L, Guo, S, Dong, A, and Liang, X.J*. Polycationic Nanoparticles as Nonviral Vectors Employed for Gene Therapy In Vivo. Mini-Reviews in Medicinal Chemistry. 2010, 10(2):126-37.

  43. Tan, J.J., Cong, X.J., Hu, L.M., Wang, C.X., Jia, L and Liang, X.J*. Therapeutic Strategies Underpinning the Development of Novel Techniques for the Treatment of HIV Infection. Drug Discovery Today. 2010. 15(5): 186-197.

  44. Yin, JJ., Lao, F., Meng, J., Fu, PP., Zhao, YL, Xing G, Gao X, Sun, B, Wang, PC., Chen, C, Liang, XJ*. Inhibition of Tumor Growth by Polyhydroxylated Endohedral Metallofullerenol Nanoparticles Optimized as Reactive Oxygen Species Scavenger. Molecular Pharmacology. 2008, 74: 1132-1140.

  1. Liang, X. J.*, Shen, D.W., Yin, J.J., Aszalos, A., and Gottesman, M. M. SIRT1 contributes to cisplatin resistance in cancer cells by altering mitochondrial metabolism. Molecular Cancer Research. 2008, 6(9):1499-1506.

  2. Liang, X.J., Choi, Y., Sackett, D.L. and Park, J.K. Inhibition of stathmin enhances CCNU blocking glioma cell migration and invasion. Cancer Research. 2008, 68(13):5267-5272.

  3. Hall MD, Okabe M, Shen, DW, Liang, XJ, and Gottesman, MM. The Role of Cellular Accumulation in Determining Sensitivity to Platinum-Based Chemotherapy. Annual Review of Pharmacology and Toxicology. 200848: 495-535.

  4. Ngo.T.B*, Peng T., *, Liang X.J *., Akeju O., Pastorino S., Zhang W., Fine H.A., Maric D., Wen P.Y., Girolami U.D., Black P.M., Wu W., Shen R.F., Kang D.W., and Park J.K. The 1p encoded protein stathmin modulates the response of malignant gliomas to nitrosoureas. Journal of National Cancer Institute. 2007, 99: 639-652.

  5. Liang, X. J., Mukherjee, S., Shen, D. W., Maxfield, F. R. and Gottesman, M. M. Endocytic Recycling Compartments Altered in Cisplatin-Resistant Cancer Cells . Cancer Research. 2006, 66 (4): Feb 15; 2346-2353.

  6. Liang, X. J., Shen, D. W., Chen G. K., Wincovitch S. M., Garfield, S., and Gottesman, M. M. Trafficking and localization of platinum complexes in cisplatin-resistant cell lines monitored by fluorescence-labeled platinum. Journal of Cellular Physiology. 2005, 202 (3): 635-641.

  7. Liang, X.J, Shen, D.W, and Gottesman, M.M. Down-regulation and altered localization of -catenin in cisplatin-resistant adenocarcinoma cells. Molecular Pharmacology. 2004 65 (5): 1217-1224.

  8. Liang, X.J, Shen, D.W, and Gottesman, M.M. A pleiotropic defect reducing drug accumulation in cisplatin-resistant cells. Journal of Inorganic Biochemistry. 2004 (98) 1599-1606.

  9. Liang, X.J, Yin, J.J., Zhou, J.W., Wang, P. C., Taylor, B., Cardarelli, C., Kozar, M, Forte, R., Aszalos, A. and Gottesman, M. M. Changes in biophysical parameters of plasma membranes influence cisplatin resistance of sensitive and resistant epidermal carcinoma cells. Experimental Cell Research. 2004, 293: 283-291.

  10. Liang, X. J., Shen, D. W., Garfield, S., and Gottesman, M. M. Mislocalization of membrane proteins associated with multidrug resistance in cisplatin-resistanct cancer cell lines. Cancer Research. 2003, 63: 5909-5916.

Book Chapters:

  1. Gottesman, M.M., Hall, M.D., Liang, X.J., and Shen, D.W.: Resistance to Cisplatin Results from Multiple Mechanisms in Cancer Cells. In Bonetti, A. Leone, R. Muggia, F. Howell, S.B. (Eds.): Platinum and Other Heavy Metal Compounds in Cancer Chemotherapy: Molecular Mechanisms and Clinical Applications. Humana Press, Totowa, New Jersey, 2009, 83-88.

  2. Liang, X.J., Chen, C.Y., Zhao, Y.L., Wang, P.C. Circumventing tumor resistance to chemotherapy by nanotechnology. Multi-Drug Resistance in Cancer Series: Methods in Molecular Biology , Zhou, Jun (Ed.), Humana Publisher, New York, 2010; 596: 467-488.

  3. Jian Jun Tan, Chang Liu, Li Ming Hu, Cun Xin Wang and Xing-Jie Liang. The State of the Science: a 5-Year Review on the Computer-Aided Design for Global Anti-AIDS Drug Development. HIV-infection - Impact, Awareness and Social Implications of living with HIV/AIDS, Eugenia Barros (Edited), 2011, INTECH open access publisher, ISBN978-953-307-343-9. 2011, 25-46.

  4. Liang, X.J. Editing “Nanopharmaceuticals: Potential Application of Nanomaterials. (approx. 800pp) World Scientific Publication Press, New Jersey, 2012. ISBN: 978-981-436-866-7.

  5. Xue Xue, Xing-Jie Liang.Multifunctional Nanoparticles for Theranostics and Imaging. Nanomedicine: Nanostructure Science and Technology 2014, pp 101-115.

  6. 梁兴杰、 杨科妮、李盛亮、王重夕、金叔宾等。第6章 纳米辅料的药学应用。阎锡蕴主编 科学出版社。2014. Page 281-336

Community service:
Chinese Society of Biophysics; Chinese Pharmaceutical Association;American Association for Cancer Research;American Society for Cell Biology;Association of the International Union against Cancer;International Society of Nanomedicine

Commitment to research the situation:

1.International Collaborative Nano-program of China and Finland, 2008-2010.  2.973 Program (National Key Science and Technology Plan) of Chinese Ministry of Science and Technology, 2009-2013 Chief Scientist. 3. National Natural Science Foundation of China (Key Program)2014-2017,  Principal Investigator.  4. “863” program (National Program of Gene Therapy) of Chinese Ministry of Science and Technology, 2012-2016Program Investigator. 5. National Natural Science Foundation of China (National Distinguished Young Scholars Program)2013-2016,  Principal Investigator. 6. Strategic Piority Research Program of Chinese Academy of Sciences, 2013-2017, Chief Scientist of Nanopharmaceutical Program.